As of 2024-07-27, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (230.78) USD. This relative valuation is based on P/E multiples. With the latest stock price at 44.86 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -614.4%.
The range of the Relative Valuation is (208.49) - (204.56) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.8x - 47.7x | 39.8x |
| Forward P/E multiples | 30.1x - 31.2x | 30.6x |
| Fair Price | (208.49) - (204.56) | (230.78) |
| Upside | -564.8% - -556.0% | -614.4% |
| Date | P/E |
| 2024-07-26 | -6.84 |
| 2024-07-25 | -6.87 |
| 2024-07-24 | -6.88 |
| 2024-07-23 | -6.89 |
| 2024-07-22 | -6.78 |
| 2024-07-19 | -6.49 |
| 2024-07-18 | -6.53 |
| 2024-07-17 | -6.69 |
| 2024-07-16 | -6.90 |
| 2024-07-15 | -6.78 |
| 2024-07-12 | -6.89 |
| 2024-07-11 | -6.69 |
| 2024-07-10 | -6.48 |
| 2024-07-09 | -6.44 |
| 2024-07-08 | -6.33 |
| 2024-07-05 | -6.24 |
| 2024-07-03 | -6.13 |
| 2024-07-02 | -6.25 |
| 2024-07-01 | -6.27 |
| 2024-06-28 | -6.27 |
| 2024-06-27 | -6.32 |
| 2024-06-26 | -6.18 |
| 2024-06-25 | -6.08 |
| 2024-06-24 | -6.01 |
| 2024-06-21 | -6.04 |
| 2024-06-20 | -5.80 |
| 2024-06-18 | -5.71 |
| 2024-06-17 | -6.07 |
| 2024-06-14 | -5.96 |
| 2024-06-13 | -6.58 |
| 2024-06-12 | -6.81 |
| 2024-06-11 | -6.31 |
| 2024-06-10 | -6.40 |
| 2024-06-07 | -6.31 |
| 2024-06-06 | -6.37 |
| 2024-06-05 | -6.32 |
| 2024-06-04 | -6.24 |
| 2024-06-03 | -6.27 |
| 2024-05-31 | -6.12 |
| 2024-05-30 | -5.90 |
| 2024-05-29 | -5.82 |
| 2024-05-28 | -6.00 |
| 2024-05-24 | -6.15 |
| 2024-05-23 | -6.09 |
| 2024-05-22 | -6.27 |
| 2024-05-21 | -6.19 |
| 2024-05-20 | -6.33 |
| 2024-05-17 | -6.39 |
| 2024-05-16 | -6.50 |
| 2024-05-15 | -6.27 |